Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Free Cash Flow (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Free Cash Flow data on record, last reported at -$20.0 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 185.71% year-over-year to -$20.0 million; the TTM value through Dec 2025 reached -$42.0 million, up 16.0%, while the annual FY2024 figure was $36.0 million, 111.69% up from the prior year.
  • Free Cash Flow reached -$20.0 million in Q3 2025 per INDV's latest filing, down from -$17.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$4.0 million in Q2 2024 and bottomed at -$39.0 million in Q1 2024.